Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oscient Pharmaceuticals has acquired worldwide rights to Pfizer's Ramoplanin, currently in development for the potential treatment of Clostridium difficile-associated disease.
Subscribe to our email newsletter
The new worldwide licensing agreement expands a previous one, under which Oscient had rights to the drug in the US and Canada only. Oscient will now assume full control of Ramoplanin manufacturing, development and commercialization on a global basis.
Oscient recently agreed on a special protocol assessment (SPA) with the FDA for the phase III program of Ramoplanin.
“Acquiring worldwide rights to Ramoplanin is a major milestone for Oscient,” stated Steven Rauscher, president and CEO of Oscient Pharmaceuticals. “With full ownership of Ramoplanin, we have significantly strengthened our asset portfolio and, after securing a long-term source of product supply, will be poised to advance the product candidate into phase III development.”
In exchange for the expanded worldwide rights, Oscient has made a one-time, up-front payment to Pfizer, and will make additional payments upon the achievement of specified regulatory milestones and for royalties on net sales. Pfizer has agreed to transfer the technological know-how related to the manufacture of Ramoplanin.